Home › NDC Lookup › RxCUI directory › RxCUI 2571805

1.5 ML somapacitan-beco 3.3 MG/ML Pen Injector [Sogroya] — RxCUI 2571805

Name: 1.5 ML somapacitan-beco 3.3 MG/ML Pen Injector [Sogroya] (RxCUI 2571805)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2571805 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2571805

Official name1.5 ML somapacitan-beco 3.3 MG/ML Pen Injector [Sogroya]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asSogroya 5 MG per 1.5 ML Pen Injector; Sogroya 5 MG in 1.5 ML Pen Injector; Sogroya 3.3 MG/ML per 1.5 ML Pen Injector

FDA products mapped3

Package NDCs mapped6

Reported Medicaid activity (SDUD)7,035 prescriptions · 30 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Somapacitan-beco Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Sogroya is specifically designed to last longer in the body. It attaches to a natural blood protein called albumin, which slows its breakdown so one weekly shot provides steady lev...
Why does my doctor have me inject Sogroya only once a week instead of every day like older growth hormone shots?
You can inject Sogroya into the upper arm, thigh, abdomen, or buttocks — all are approved injection sites. What really matters is rotating the spot each week. Using the same area r...
Where exactly do I inject it, and does it matter if I use the same spot every week?

📖 Read our full Somapacitan-beco Injection guide →

🕸️ Concept Web — How 1.5 ML somapacitan-beco 3.3 MG/ML Pen Injector [... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 1.5 ML somapacitan-beco 3.3 MG/ML Pen Injector [Sogroya] RxCUI 2571805 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Somapacitan 2557373 IN
- Somapacitan-beco 2557394 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Sogroya 2557399 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Somapacitan Pen Injector 2557397 SCDF
- Somapacitan-beco Pen Injector 2647700 SCDFP
- Somapacitan Injectable Product 2557396 SCDG
- Somapacitan-beco Injectable Product 2662297 SCDGP
- Somapacitan Pen Injector [Sogroya] 2557401 SBDF
- Somapacitan-beco Pen Injector [Sogroya] 2655534 SBDFP
- Sogroya Injectable Product 2557402 SBDG
- Pen Injector 1649571 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 1.5 ML somapacitan-beco 3.3 MG/ML Pen Injector 2571802 SCD
- Somapacitan-beco 3.3 MG/ML 2571801 SCDC
- Somapacitan-beco 3.3 MG/ML [Sogroya] 2571804 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

1.5 ML somapacitan-beco 3.3 MG/ML Pen Injector SCD · 2571802
Somapacitan-beco 3.3 MG/ML SCDC · 2571801
Somapacitan Pen Injector SCDF · 2557397
Somapacitan-beco Pen Injector SCDFP · 2647700
Somapacitan Injectable Product SCDG · 2557396
Somapacitan-beco Injectable Product SCDGP · 2662297

Brand-Name Concepts

Somapacitan-beco 3.3 MG/ML [Sogroya] SBDC · 2571804
Somapacitan Pen Injector [Sogroya] SBDF · 2557401
Somapacitan-beco Pen Injector [Sogroya] SBDFP · 2655534
Sogroya Injectable Product SBDG · 2557402
Sogroya BN · 2557399

📦 FDA Products & Package NDCs

3 products · 6 package NDCs

6 package NDCs map to RxCUI 2571805 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00169-2030-11	1 SYRINGE, PLASTIC in 1 CARTON (0169-2030-11) / 1.5 mL in 1...	SOGROYA	Novo Nordisk	2023-05-01
00169-2030-90	1 SYRINGE, PLASTIC in 1 CARTON (0169-2030-90) / 1.5 mL in 1...	SOGROYA	Novo Nordisk	2023-05-01
00169-2035-11	1 SYRINGE, PLASTIC in 1 CARTON (0169-2035-11) / 1.5 mL in 1...	SOGROYA	Novo Nordisk	2023-05-01
00169-2035-90	1 SYRINGE, PLASTIC in 1 CARTON (0169-2035-90) / 1.5 mL in 1...	SOGROYA	Novo Nordisk	2023-05-01
00169-2037-11	1 SYRINGE, PLASTIC in 1 CARTON (0169-2037-11) / 1.5 mL in 1...	SOGROYA	Novo Nordisk	2023-05-01
00169-2037-90	1 SYRINGE, PLASTIC in 1 CARTON (0169-2037-90) / 1.5 mL in 1...	SOGROYA	Novo Nordisk	2023-05-01

Observed labelers: Novo Nordisk (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.